School of Public Health, and Director of the Child and Adolescent Population Health Program at UT Southwestern
Cost a barrier Dr Deb Cohen-Jones believes once supply issues have been fixed, long-acting glutides will lead the way in 2023 due to their efficacy and tolerability among users
5 Among adherent participants, average weight loss was 20.7% at 7.2 mg compared with 17.5% at 2.4 mg over 72 weeks
However, the safety and efficacy of these combinations have not been extensively studied, and the decision to use multiple weight loss drugs should be made under close supervision by a qualified healthcare provider
Patients taking insulin or sulfonylureas should be particularly vigilant about hypoglycemia risk if nausea reduces food intake, and may need adjustment of these medications
Some practitioners implement cycling to theoretically prevent receptor desensitization, provide physiological breaks, or manage costs, though evidence supporting these approaches is limited
